Published in Clin J Am Soc Nephrol on January 16, 2008
Plasma volume, albumin, and fluid status in peritoneal dialysis patients. Clin J Am Soc Nephrol (2010) 1.02
A study of the clinical and biochemical profile of peritoneal dialysis fluid low in glucose degradation products. Perit Dial Int (2011) 0.94
The effects of low-sodium peritoneal dialysis fluids on blood pressure, thirst and volume status. Nephrol Dial Transplant (2009) 0.85
N-terminal pro-B-type natriuretic peptide variability in stable dialysis patients. Clin J Am Soc Nephrol (2015) 0.79
Baseline hydration status in incident peritoneal dialysis patients: the initiative of patient outcomes in dialysis (IPOD-PD study)†. Nephrol Dial Transplant (2015) 0.78
Overhydration Is a Strong Predictor of Mortality in Peritoneal Dialysis Patients - Independently of Cardiac Failure. PLoS One (2016) 0.75
B-type natriuretic peptide and prognosis of end-stage renal disease: a meta-analysis. PLoS One (2013) 0.75
Biomarkers in predicting mortality and treatment in hemodialysis patients. F1000 Med Rep (2009) 0.75
Plasma natriuretic peptide levels and the risk of cardiovascular events and death. N Engl J Med (2004) 7.12
Treatment of heart failure guided by plasma aminoterminal brain natriuretic peptide (N-BNP) concentrations. Lancet (2000) 6.01
The prognostic value of B-type natriuretic peptide in patients with acute coronary syndromes. N Engl J Med (2001) 5.50
Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol (2002) 4.59
Impact of obesity on plasma natriuretic peptide levels. Circulation (2004) 4.46
B-type natriuretic peptide predicts sudden death in patients with chronic heart failure. Circulation (2002) 4.30
N-terminal pro-B-type natriuretic peptide and long-term mortality in stable coronary heart disease. N Engl J Med (2005) 3.35
Relative contribution of residual renal function and peritoneal clearance to adequacy of dialysis: a reanalysis of the CANUSA study. J Am Soc Nephrol (2001) 3.26
B-type natriuretic peptides and ejection fraction for prognosis after myocardial infarction. Circulation (2003) 2.22
The use of B-type natriuretic peptide to assess volume status in patients with end-stage renal disease. Am Heart J (2007) 1.69
Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol (2003) 1.64
Association between C-reactive protein levels and N-terminal pro-B-type natriuretic peptide in pre-dialysis patients. Nephron Clin Pract (2004) 1.54
Amino-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide: biomarkers for mortality in a large community-based cohort free of heart failure. Hypertension (2006) 1.52
Cardiac natriuretic peptides are related to left ventricular mass and function and predict mortality in dialysis patients. J Am Soc Nephrol (2001) 1.46
Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial. Kidney Int (2005) 1.40
Diagnostic accuracy and prognostic relevance of the measurement of cardiac natriuretic peptides: a review. Clin Chem (2003) 1.39
Circulating natriuretic peptide concentrations in patients with end-stage renal disease: role of brain natriuretic peptide as a biomarker for ventricular remodeling. Mayo Clin Proc (2001) 1.29
Cardiac endocrine function is an essential component of the homeostatic regulation network: physiological and clinical implications. Am J Physiol Heart Circ Physiol (2006) 1.28
Diagnostic and prognostic value of plasma brain natriuretic peptide in non-dialysis-dependent CRF. Am J Kidney Dis (2004) 1.20
N-terminal pro-brain natriuretic peptide: an independent risk predictor of cardiovascular congestion, mortality, and adverse cardiovascular outcomes in chronic peritoneal dialysis patients. J Am Soc Nephrol (2006) 1.14
N-terminal pro-B-type natriuretic peptide and B-type natriuretic peptide for identifying coronary artery disease and left ventricular hypertrophy in ambulatory chronic kidney disease patients. Am J Cardiol (2006) 1.11
The prognostic role of brain natriuretic peptides in hemodialysis patients. Am J Nephrol (2002) 1.10
Increased circulating levels of natriuretic peptides predict future cardiac event in patients with chronic hemodialysis. Nephron (2002) 1.08
Prognostic value of combined use of biomarkers of inflammation, endothelial dysfunction, and myocardiopathy in patients with ESRD. Kidney Int (2005) 1.08
Deconvolution analysis of cardiac natriuretic peptides during acute volume overload. Hypertension (2000) 1.00
Cardiac biomarkers and survival in haemodialysis patients. Eur J Clin Invest (2007) 0.99
Diagnostic potential of cardiac natriuretic peptides in dialysis patients. Kidney Int (2001) 0.99
Plasma brain natriuretic peptide levels in chronic hemodialysis patients: influence of coronary artery disease. Am J Kidney Dis (2001) 0.97
Association between serum n-terminal pro-brain natriuretic peptide concentration and left ventricular dysfunction and extracellular water in continuous ambulatory peritoneal dialysis patients. Perit Dial Int (2006) 0.96
Association between brain natriuretic peptide and extracellular water in hemodialysis patients. Nephron Clin Pract (2003) 0.96
Natriuretic peptides and the dialysis patient. Semin Dial (2005) 0.96
Brain natriuretic peptide and N-terminal proBNP in chronic haemodialysis patients. Nephron Clin Pract (2006) 0.95
Comparison of body fluid distribution between chronic haemodialysis and peritoneal dialysis patients as assessed by biophysical and biochemical methods. Nephrol Dial Transplant (2001) 0.94
Diagnostic potential of circulating natriuretic peptides in chronic kidney disease. Nephrol Dial Transplant (2005) 0.92
Plasma concentration of human brain natriuretic peptide in patients on hemodialysis. Am J Kidney Dis (1994) 0.91
Plasma concentration of brain natriuretic peptide as an indicator of cardiac ventricular function in patients on hemodialysis. Am J Nephrol (1998) 0.90
Natriuretic peptides and cardiovascular events: more than a stretch. JAMA (2007) 0.90
Value of B-type natriuretic peptide in diagnosing left ventricular dysfunction in dialysis-dependent patients. Intern Med J (2006) 0.85
Significance of brain natriuretic peptides in patients on continuous ambulatory peritoneal dialysis. Int J Mol Med (2002) 0.83
Adrenomedullin reflects cardiac dysfunction, excessive blood volume, and inflammation in hemodialysis patients. Kidney Int (2005) 0.81
NT-ProBNP in outpatients after myocardial infarction: interaction between symptoms and left ventricular function and optimized cut-points. J Card Fail (2005) 0.80
Differential regulation of brain and atrial natriuretic peptides in hemodialysis patients. Clin Nephrol (1993) 0.79
Neuropeptide-Y and atrial natriuretic peptide as prognostic markers in patients on hemodialysis. ASAIO J (2003) 0.79
Clinical significance of natriuretic peptides and cyclic GMP in hemodialysis patients with coronary artery disease. Am J Nephrol (2001) 0.78
Natriuretic peptides in acute and chronic kidney disease and during renal replacement therapy. J Investig Med (2005) 0.78
Relationship between Doppler transmitral flow velocity pattern and plasma atrial and brain natriuretic peptide concentrations in anuric patients on maintenance hemodialysis. Int Heart J (2006) 0.77
Changes in brain natriuretic peptide and atrial natriuretic peptide plasma concentrations during hemodialysis in patients with chronic renal failure. Horm Metab Res (1994) 0.77
B-type natriuretic peptide (BNP) or N-terminal-proBNP for the diagnosis of heart failure: which peptide is the better choice? Scand J Clin Lab Invest (2005) 0.77
Changes in plasma atrial natriuretic peptide during hemodialysis: mechanism of elevated levels in patients with chronic renal failure. Endocr J (1993) 0.76
Plasma levels of human atrial natriuretic factor in patients treated by hemodialysis and continuous ambulatory peritoneal dialysis. Nephron (1988) 0.76
Endothelin and atrial natriuretic peptide in non-insulin-dependent diabetic versus nondiabetic patients on chronic hemodialysis. Ren Fail (1994) 0.76
Brain natriuretic peptide and its relationship to left ventricular hypertrophy in patients on peritoneal dialysis or hemodialysis less than 3 years. Ren Fail (2006) 0.76
Effect of cinacalcet on cardiovascular disease in patients undergoing dialysis. N Engl J Med (2012) 8.88
Peritoneal dialysis-related infections recommendations: 2005 update. Perit Dial Int (2005) 5.49
Effects of increased peritoneal clearances on mortality rates in peritoneal dialysis: ADEMEX, a prospective, randomized, controlled trial. J Am Soc Nephrol (2002) 4.59
Similar outcomes with hemodialysis and peritoneal dialysis in patients with end-stage renal disease. Arch Intern Med (2010) 3.78
Chronic kidney disease and cardiovascular risk: epidemiology, mechanisms, and prevention. Lancet (2013) 3.44
Perceived knowledge among patients cared for by nephrologists about chronic kidney disease and end-stage renal disease therapies. Kidney Int (2008) 3.36
A randomized double-blind trial to compare the efficacy of teriparatide [recombinant human parathyroid hormone (1-34)] with alendronate in postmenopausal women with osteoporosis. J Clin Endocrinol Metab (2002) 2.16
Hemodialysis vascular access modifies the association between dialysis modality and survival. J Am Soc Nephrol (2011) 2.13
Hemodialysis and peritoneal dialysis are associated with similar outcomes for end-stage renal disease treatment in Canada. Nephrol Dial Transplant (2012) 2.07
NT-proBNP, fluid volume overload and dialysis modality are independent predictors of mortality in ESRD patients. Nephrol Dial Transplant (2009) 2.06
The outcomes of continuous ambulatory and automated peritoneal dialysis are similar. Kidney Int (2009) 1.98
Patient education and access of ESRD patients to renal replacement therapies beyond in-center hemodialysis. Kidney Int (2005) 1.85
Inflammation and extracellular volume expansion are related to sodium and water removal in patients on peritoneal dialysis. Perit Dial Int (2006) 1.70
Icodextrin improves metabolic and fluid management in high and high-average transport diabetic patients. Perit Dial Int (2009) 1.64
Survival of functionally anuric patients on automated peritoneal dialysis: the European APD Outcome Study. J Am Soc Nephrol (2003) 1.64
Comparison of a technique using a new percutaneous osteosynthesis device with conventional open surgery for displaced patella fractures in a randomized controlled trial. J Orthop Trauma (2006) 1.60
Differential effects of teriparatide and alendronate on bone remodeling in postmenopausal women assessed by histomorphometric parameters. J Bone Miner Res (2005) 1.57
Serum markers of low-turnover bone disease in Mexican children with chronic kidney disease undergoing dialysis. Perit Dial Int (2006) 1.50
Patient and technique survival on peritoneal dialysis in the United States: evaluation in large incident cohorts. Kidney Int Suppl (2003) 1.42
[Hyperleptinemia as a risk factor in obesity-related hypertension]. Med Clin (Barc) (2004) 1.42
Health-related quality of life predicts outcomes but is not affected by peritoneal clearance: The ADEMEX trial. Kidney Int (2005) 1.40
Evaluation of Cinacalcet Therapy to Lower Cardiovascular Events (EVOLVE): rationale and design overview. Clin J Am Soc Nephrol (2007) 1.34
Impact of initial dialysis modality and modality switches on Medicare expenditures of end-stage renal disease patients. Kidney Int (2005) 1.30
Superiority of icodextrin compared with 4.25% dextrose for peritoneal ultrafiltration. J Am Soc Nephrol (2004) 1.18
Prevention of chronic kidney and vascular disease: toward global health equity--the Bellagio 2004 Declaration. Kidney Int Suppl (2005) 1.16
Health-related quality of life and hemoglobin levels in chronic kidney disease patients. Clin J Am Soc Nephrol (2008) 1.14
Comparison between bicarbonate/lactate and standard lactate dialysis solution in peritoneal transport and ultrafiltration: a prospective, crossover single-dwell study. Perit Dial Int (2008) 1.14
Risk factors for prostate cancer detection after a negative biopsy: a novel multivariable longitudinal approach. J Clin Oncol (2010) 1.10
Percutaneous renal biopsy of native kidneys: efficiency, safety and risk factors associated with major complications. Arch Med Sci (2011) 1.08
Metabolic and laboratory effects of icodextrin. Kidney Int Suppl (2002) 1.06
Baseline characteristics of subjects enrolled in the Evaluation of Cinacalcet HCl Therapy to Lower Cardiovascular Events (EVOLVE) trial. Nephrol Dial Transplant (2012) 1.01
The clinical course of treated hyperparathyroidism among patients receiving hemodialysis and the effect of cinacalcet: the EVOLVE trial. J Clin Endocrinol Metab (2013) 0.98
Review of clinical trial experience with icodextrin. Kidney Int Suppl (2002) 0.96
Pharmacokinetics of icodextrin in peritoneal dialysis patients. Kidney Int Suppl (2002) 0.94
Overview of peritoneal dialysis in Latin America. Perit Dial Int (2007) 0.92
Relation between pesticide exposure and intrauterine growth retardation. Chemosphere (2004) 0.92
Use of icodextrin in high transport ultrafiltration failure. Kidney Int Suppl (2002) 0.91
Markers of inflammation before and after renal transplantation. Transplantation (2005) 0.90
A soy protein diet alters hepatic lipid metabolism gene expression and reduces serum lipids and renal fibrogenic cytokines in rats with chronic nephrotic syndrome. J Nutr (2002) 0.89
A call for quality research on salt intake and health: from the World Hypertension League and supporting organizations. J Clin Hypertens (Greenwich) (2014) 0.88
Angiogenic and inflammatory markers in acute respiratory distress syndrome and renal injury associated to A/H1N1 virus infection. Exp Mol Pathol (2013) 0.88
Chronic kidney disease and dialysis in Mexico. Perit Dial Int (2007) 0.86
Soy protein diet ameliorates renal nitrotyrosine formation and chronic nephropathy induced by puromycin aminonucleoside. Life Sci (2004) 0.86
Cardiovascular risk factors and prevention of cardiovascular disease in patients with chronic renal disease. Expert Opin Pharmacother (2010) 0.86
Impact of fill volume on peritoneal clearances and cytokine appearance in peritoneal dialysis. Perit Dial Int (2004) 0.86
Profiling of peritoneal ultrafiltration. Kidney Int Suppl (2002) 0.86
Prevalence of hepatitis C virus infection among hemodialysis patients at a tertiary-care hospital in Mexico City, Mexico. J Clin Microbiol (2004) 0.85
Clinical practice guidelines for the prevention, diagnosis, evaluation and treatment of mineral and bone disorders in chronic kidney disease (CKD-MBD) in adults. Nefrologia (2013) 0.85
Renoprotective and antihypertensive effects of S-allylcysteine in 5/6 nephrectomized rats. Am J Physiol Renal Physiol (2007) 0.83
Inflammation in patients on peritoneal dialysis is associated with increased extracellular fluid volume. Arch Med Res (2004) 0.83
Proposed nomenclature for salt intake and for reductions in dietary salt. J Clin Hypertens (Greenwich) (2014) 0.82
C-reactive protein and anti-Chlamydia pneumoniae antibodies as risk factors of cardiovascular death in incident patients on peritoneal dialysis. Perit Dial Int (2003) 0.81
Drug treatment of hypertension: compliance and adverse reactions in a cohort of hypertensive patients in a primary care setting. Rev Invest Clin (2007) 0.81
Inflammation and oxidative stress markers by pentoxifylline treatment in rats with chronic renal failure and high sodium intake. Arch Med Res (2007) 0.80
Dialysis disequilibrium syndrome and other treatment complications of extreme uremia: a rare occurrence yet not vanished. Hemodial Int (2008) 0.79
Why is the evidence favoring hemodialysis over peritoneal dialysis misleading? Semin Dial (2007) 0.79
Induction of suppressive allogeneic regulatory T cells via rabbit antithymocyte polyclonal globulin during homeostatic proliferation in rat kidney transplantation. Transpl Int (2014) 0.79
Changes in free water fraction and aquaporin function with dwell time during continuous ambulatory peritoneal dialysis. Artif Organs (2010) 0.79
[Early referral to the nephrologist: impact on initial hospitalization and the first 6 months of continuous ambulatory peritoneal dialysis]. Rev Invest Clin (2004) 0.79
Comparative study of enalapril vs. losartan on residual renal function preservation in automated peritoneal dialysis. A randomized controlled study. Rev Invest Clin (2012) 0.78
Effect of parathyroidectomy on cardiac fibrosis and apoptosis: possible role of aldosterone. Nephron Physiol (2006) 0.78
[Bioimpedance vector analysis for body composition in Mexican population]. Rev Invest Clin (2007) 0.78
Chronotherapy in hypertension: a pill at night makes things right? J Am Soc Nephrol (2011) 0.78
Future of icodextrin as an osmotic agent in peritoneal dialysis. Kidney Int Suppl (2002) 0.78
C.E.R.A. maintains stable hemoglobin in Latin American patients on dialysis. Int Urol Nephrol (2012) 0.78
[Is a calcineurin inhibitor required as part of the immunosuppression scheme in kidney transplant recipients that share 2-haplotypes with their donors?]. Rev Invest Clin (2010) 0.78
[Systemic hypertension after kidney transplantation: associated risk factors and influence on graft survival]. Gac Med Mex (2005) 0.77
Relationship of insulin resistance and overweight with cortisol and dehydroepiandrosterone-sulfate levels. Arch Med Res (2002) 0.77
[Clinical and laboratorial predictors related to progression to chronic kidney disease in patients with autosomal dominant polycystic kidney disease]. Rev Invest Clin (2010) 0.77
Conjugated estrogens and tibolone modify the gonadotrophin glycosylation pattern in postmenopausal women. Gynecol Obstet Invest (2006) 0.77
Efforts to reduce dietary salt in the Americas. Rev Panam Salud Publica (2012) 0.77
Association of vitamin D receptor polymorphisms with osteoporosis in mexican postmenopausal women. Hum Biol (2003) 0.77
Survival advantage of icodextrin peritoneal dialysis solution in a time-dependent model. Am J Kidney Dis (2012) 0.77
In vivo IL-10 and TGF-beta production by PBMC from long-term kidney transplant recipients with excellent graft function: a possible feedback mechanism participating in immunological stability. Clin Transplant (2004) 0.77
Prevention strategies for chronic kidney disease in Latin America: a strategy for the next decade--a report on the Villarica Conference. Ren Fail (2006) 0.77
Urinary neutrophil gelatinase-associated lipocalin predicts graft loss after acute kidney injury in kidney transplant. Biomarkers (2013) 0.77
The first report of The Latin American Society of Nephrology and Hypertension (SLANH) Anemia Committee in chronic hemodialysis patients. Nefrologia (2013) 0.77
Molecularly targeted therapy for Kaposi's sarcoma in a kidney transplant patient: case report, "what worked and what did not". BMC Nephrol (2007) 0.77
Advancing fluid management in peritoneal dialysis. Kidney Int Suppl (2002) 0.77
Genetic factors play an important role in the pathogenesis of hyperlipidemia post-transplantation. Am J Kidney Dis (2002) 0.77
Risk factors for infections requiring hospitalization in renal transplant recipients: a cohort study. Int J Infect Dis (2011) 0.77
Assessing creatinine clearance from modification of diet in renal disease study equations in the ADEMEX cohort: limitations and potential applications. Clin J Am Soc Nephrol (2010) 0.76
What are the problems with using the peritoneal membrane for long-term dialysis? Semin Dial (2008) 0.76
Treatment of type 2 diabetes in primary health care: a drug utilization study. Ann Pharmacother (2005) 0.76
Proinflammatory gene expression and renal lipogenesis are modulated by dietary protein content in obese Zucker fa/fa rats. Am J Physiol Renal Physiol (2010) 0.76
Renal Thrombotic Microangiopathy in Proliferative Lupus Nephritis: Risk Factors and Clinical Outcomes: A Case-Control Study. J Clin Rheumatol (2016) 0.75
Renal replacement therapy in the developing world: are we on the right track, or should there be a new paradigm? J Am Soc Nephrol (2007) 0.75
Basiliximab vs. limited-dose daclizumab (2 mg/kg) administered in single or two separated doses in kidney transplantation. Rev Invest Clin (2008) 0.75